Hybrid corporate governance and its effects on innovation: A case study of AstraZeneca

Technology Analysis and Strategic Management

Volumn 16, Issue 1, 2004, Pages 97-119

  Ramirez, Paulina ^a   Tylecote, Andrew ^b  

^a NATIONAL UNIVERSITY OF IRELAND   (Ireland)

^b UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GOVERNANCE APPROACH; INNOVATION; PHARMACEUTICAL INDUSTRY;

EURASIA; EUROPE; NORTH AMERICA; NORTHERN EUROPE; SCANDINAVIA; SWEDEN; UNITED KINGDOM; UNITED STATES; WESTERN EUROPE;

EID: 1542319859     PISSN: 09537325     EISSN: None     Source Type: Journal    
DOI: 10.1080/0953732032000175535     Document Type: Article

References (28)

1. A. Tylecote & E. Conesa, Corporate governance, innovation systems and industrial performance, Industry and Innovation, 6(1), June 1999, pp. 25-50.
2. A. Bassanini & E. Ekkehard, Labour market regulation, industrial relations and technological regimes: a tale of comparative advantage. Industrial and Corporate Change, 11, 2002, pp. 391-426.
3. J. Howells & I. Neary, Intervention and Technological Innovation; Government and the Pharmaceutical Industry in the UK and Japan (MacMillan Press, London, 1995).
4. A. Jungmittag, G. Reger & R. Thomas. Changing Innovation in the Pharmaceutical Industry: Globalization and New Ways of Drug Development (Springer, Berlin, 2000);
5. P. Ramirez, Globalisation, technology and organisational change in the pharmaceutical industry, DPhil Thesis, University of Manchester Institute of Science and Technology, 2003.
6. P. Ramirez & A. Tylecote, The globalisation of innovation and corporate governance in pharmaceuticals: the shift of European investment to the USA, Paper presented to the ASEAT/Institute of Innovation Research Conference 'Knowledge and Economic and Social Change; New Challenges to Innovation Studies', Manchester. 7-9 April 2003.
7. P. Ramirez & A. Tylecote, Technological change in the pharmaceutical industry: a literature review from the view of corporate governance, Corporate Governance and Product Innovation, Report for the European Commission (DGXII). Targeted Socio-Economic Research (TSER), 1999.
8. M. Sharp & I. Galimberti, Coherence and diversity: Europe's chemical giants and the assimilation of biotechnology. STEEP Discussion Paper No. 5, 1993, Science Policy Research Unit;
9. P. Nightingale, Knowledge and technical change: computer simulations and the changing innovation process, PhD Thesis, 1997, Sussex University;
10. V. Walsh, P. Ramirez & G. Tampubolon, Globalisation, technological change and the pharmaceutical industry, Paper presented at EAEPE 1998 Conference, 5-8 November 1998, Lisbon, Portugal;
11. L. Orsenigo, F. Pammollo & M. Riccaboni, Technological change and network dynamics: lessons from the pharmaceutical industry, Research Policy 30, 2001, pp. 485-508.
12. M. Sharp & P. Patel, Europe's pharmaceutical industry: an innovation profile. Draft Report prepared for the DGXIII-D4, 1996;
13. V. Walsh & G. Lodorfos, Technological and organisational innovation in chemicals and related products, Technological Analysis & Strategic Management, 14(3), 2002, pp. 273-297;
14. A. James, The strategic management of mergers and acquisitions in the pharmaceutical industry: developing a resource-based perspective, Technological Analysis & Strategic Management, 14(3), 2002, pp. 299-313;
15. S. Randles, Complex systems applied? The merger that made Glaxo SmithKline, Technological Analysis & Strategic Management, 14(3), 2002, pp. 331-354;
16. A. Jungmittag, G. Reger & R. Thomas, R., Changing Innovation in the Pharmaceutical Industry: Globalization and New Ways of Drug Development (Springer, Berlin, New York, 2000);
17. J. Howells, Innovation outsourcing and externalisation: implications for conceptualising innovation systems, Paper presented at the ESRC Centre for Research in Innovation and Competition (CRIC) 'Systems and Services Innovation Workshop', University of Manchester, March 1998 (Mimeo); Survey on the pharmaceutical industry, The Economist, 21-27 February 1998.
18. Clive Cookson, Development times static, Financial Times, 15 March 1999.
19. The Hampel Report, The Final Report, The Committee on Corporate Governance and Gee Publishing Ltd, January 1998.
20. Commission of the European Communities (CEC), Report on workplace involvement in technological innovation in the European Community. Commission of the European Communities, Vol. 1, 1990;
21. J. Solomon, A. Tylecote & A. Solomon, UK corporate governance and innovation, Corporate Governance and Product Innovation, Report for the European Commission (DGXII), Targeted Socio-Economic Research programme (TSER), 1999.
22. I. Demirag. A. Tylecote & B. Morris, Accounting for financial and managerial causes of short term pressures in British corporations. Journal of Business Finance and Accounting, 21(8), December 1994, pp. 1195-1213.
23. T.A. Lee & D.P. Tweedie, The private shareholder and the corporate report, A Report to the Research Committee of the Institute of Chartered Accountants of England and Wales. The Institute of Chartered Accountants of England and Wales, London, UK, 1977.
24. J. Holland, Private voluntary disclosures, financial intermediation and market efficiency, Journal of Business Finance and Accounting. 25(1). 1998, pp. 29-68.
25. M. Gaved, Ownership and influence, LSE Report 95.19807, 1995.
26. A. Tylecote & P. Ramirez, Corporate governance and technological change in the UK, Sheffield University Management School, Working Paper No. 2003.15.
27. P. Adolfsson, U. Ask, U. Homberg & S. Jonsson. Corporate governance in Sweden: a literature review, Corporate Governance and Product Innovation, Report for the European Commission (DGXII), Targeted Socio-Economic Research (TSER) (Gothenburg, 1999).
28. J. Marton, Accounting and Stock Markets: A Study of Swedish Accounting for International Investors and Analysis (BAS Publishing, Goteborg, 1998).